A retrospective cohort study of the effectiveness and safety of dabigatran versus rivaroxaban in overweight patients with nonvalvular atrial fibrillation.
Meixiang YuZi WangLiuliu ZongQing XuXiaoye LiQianzhou LvPublished in: International journal of clinical pharmacy (2022)
Dabigatran therapy was shown to be equally effective. It may be superior in reducing bleeding risk in an overweight population with NVAF than rivaroxaban. Further prospective studies are encouraged for analysis.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- weight loss
- direct oral anticoagulants
- weight gain
- physical activity
- heart failure
- percutaneous coronary intervention
- body mass index
- stem cells
- bone marrow
- coronary artery disease
- mitral valve
- smoking cessation
- data analysis